Clinical Trials Logo

Filter by:
NCT ID: NCT03746197 Active, not recruiting - Clinical trials for Lupus Erythematosus, Systemic

Interactive Digital Technology to Assess and Improve Cognitive Dysfunction in Patients With Systemic Lupus Erythematosus

Start date: June 6, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate whether a short interactive video game device is associated with performance on standard measures of attention and problem solving in patients with systemic lupus erythematosus(SLE). The study is also designed to see if playing the video game for four weeks improves attention and problem solving in patients with SLE.

NCT ID: NCT03745794 Active, not recruiting - Clinical trials for Pancreatic Carcinoma

Repeat Quadratus Lumborum Block to Reduce Opioid Need in Patients After Pancreatic Surgery

Start date: February 28, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies how an additional anesthetic nerve block, called a quadratus lumborum block, works to reduce the need for opioids in patients after pancreatic surgery. Giving an additional regional anesthetic after surgery may hasten the weaning process, reduce the need for opioid medications upon discharge, and reduce the risk of opioid dependence.

NCT ID: NCT03745313 Active, not recruiting - Clinical trials for Tricuspid Regurgitation

Edwards CLASP TR EFS

CLASP TR EFS
Start date: February 5, 2019
Phase: N/A
Study type: Interventional

Early feasibility study to assess the safety and performance of the Edwards PASCAL Transcatheter Valve Repair System in tricuspid regurgitation

NCT ID: NCT03745287 Active, not recruiting - Sickle Cell Disease Clinical Trials

A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease

Start date: November 27, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

This is a single-arm, open-label, multi-site, single-dose Phase 1/2/3 study in subjects with severe sickle cell disease (SCD). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) using CTX001.

NCT ID: NCT03744793 Active, not recruiting - Clinical trials for Metastatic Urothelial Carcinoma

Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer

Start date: April 11, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well pemetrexed and avelumab work in treating patients with MTAP-deficient urothelial cancer that has spread to other places in the body. Pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pemetrexed and avelumab may work better in treating patients with MTAP-deficient urothelial cancer.

NCT ID: NCT03744728 Active, not recruiting - Clinical trials for Bloodstream Infection

Genotypic Versus Phenotypic Susceptibility Testing of Positive Blood Cultures

Start date: May 23, 2019
Phase: N/A
Study type: Interventional

This study is designed as a prospective, randomized, open-label trial evaluating antimicrobial utilization, clinical outcomes, and healthcare costs among patients with positive blood cultures. Patients will be randomized to one of the following FDA-cleared devices that will be used to assess the workflow impact of fast identification (ID) and antimicrobial susceptibility testing (AST) in the microbiology lab and in the quality of care in patients: 1) Standard culture and AST of positive blood culture bottles plus the Verigene® Blood Culture Gram-positive/Gram-negative kit (BC-GP/GN); or 2) Fast ID and AST of positive blood culture bottles using the Accelerate PhenoTestâ„¢ BC kit with the Accelerate Phenoâ„¢ System.

NCT ID: NCT03744559 Active, not recruiting - Clinical trials for Nicotine Use Disorder

Behavioral Memory Modulation in Nicotine Addiction

Start date: February 4, 2019
Phase: N/A
Study type: Interventional

The purpose of the study is to see if a behavioral intervention known as retrieval-extinction training (RET) might affect craving in response to nicotine cues (e.g., pictures, videos and objects) and smoking behavior in men and women who smoke cigarettes.

NCT ID: NCT03744429 Active, not recruiting - Clinical trials for Effect of Diet on Breast Milk Composition

A Dietary Intervention to Modify Breast Milk Content in Obese Lactating Women

Start date: April 16, 2019
Phase: N/A
Study type: Interventional

This study is a nutrition research study designed to look at how healthy meals can influence the content of breast milk. Moms will be provided with meals that follow a Mediterranean diet pattern for 4 weeks. The goal of the study is to see if breast milk content changes over the 4 week period. The infants of the moms will also be included in the study to measure any changes in growth.

NCT ID: NCT03744286 Active, not recruiting - Clinical trials for Spinal Cord Injuries

Investigation Into an Innovative, Clinical Slip Inducing Device in the Chronic Incomplete Spinal Cord Population

Start date: December 1, 2018
Phase: N/A
Study type: Interventional

The objective of this project is to fully test a newly developed affordable cost variable slip inducer in the ambulatory, incomplete spinal cord population. It is a self-contained device using a moving serial plank mechanism with wheels on the underside of each plank that allow for structured slips while a person walks over the planks with a harness for safety.

NCT ID: NCT03743766 Active, not recruiting - Melanoma Clinical Trials

Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting

Start date: March 29, 2019
Phase: Phase 2
Study type: Interventional

The main goal of this study is to evaluate the antitumor activity of relatlimab and nivolumab in combination in subjects with unresectable or metastatic melanoma who have not received prior treatment with immunotherapy.